ECSP034618A - Nuevos compuestos para usarse como inhibidores de proteasa vih - Google Patents

Nuevos compuestos para usarse como inhibidores de proteasa vih

Info

Publication number
ECSP034618A
ECSP034618A EC2003004618A ECSP034618A ECSP034618A EC SP034618 A ECSP034618 A EC SP034618A EC 2003004618 A EC2003004618 A EC 2003004618A EC SP034618 A ECSP034618 A EC SP034618A EC SP034618 A ECSP034618 A EC SP034618A
Authority
EC
Ecuador
Prior art keywords
alkyl
heterocyclyl
aryl
sulfonyl
oxycarbonyl
Prior art date
Application number
EC2003004618A
Other languages
English (en)
Inventor
Joseph Armstrong Martin
Sally Redshaw
Steve Swallow
Gareth John Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034618A publication Critical patent/ECSP034618A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se revelan los compuestos de la formula general y las sales farmacéutica mente aceptables de los mismos en donde R1 es H, hidroxilo o NHR2 en donde R2 es H, alquilo, alquenilo, alquinilo, arilalquilo, heterocicliaquilo, cicloalquilo, alquil caronilo, cicloalquilo, alquil, carbonilo, heterociclil alquil carbonilo, alquil oxi carbonilo, aril alquil oxi carbonilo, heterociclil alquil oxi carbonilo, arilo, heterociclilo, sulfonilo, alquil sulfonilo, aril sulfonilo, heterociclil sulfonilo, heterociclil sulfonio o un grupo de fórmula en donde X o 0 ó S y R7 y R8 independietemente son H, alquilo, arilo, heterociclilo, aril alquilo, heterociclil alquilo o R7 y R8 junto con el átomo de nitrógeno al que están unidos forman un anillo saturado que opcionalmente contienen además un teteroátomo o un grupo en donde cuando n=0, y representa 0 ó S y R10 es H, alquilo, aril alquilo, heterociclil alquilo, arilo heterociclilo o cuando n=1, Y representa N, R9 es H o alquilo y R10 H, alquilo, aril alquilo, heterociclil alquilo, arilo, heterociclilo o R9 y R10 junto con el hetroátomo al que estan unidos forman un heterociclo, y R6 es alquilo, aril alquilo, heterociclil alquilo, alquil oxi alquilo, hidroxi alquilo, amino alqulo, fluoro alquilo y R13 es H o el residuo de un éster inorgánico y orgánico y R15 es ailo, con la excepción que, si R3, R4 y R5 son melino, R6 es terebutilo, R13 es H y si R15 es fenilo R2 no es bencil oxicarbonilo ni 2-quinolina carbonilo. Los compuestos de fórmula I son potentes inhibidores de la VIH aspartil proteasa y se pueden usar en el tratamiento de enfermedades relacionadas con VIH.
EC2003004618A 2000-11-22 2003-05-21 Nuevos compuestos para usarse como inhibidores de proteasa vih ECSP034618A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0028483.6A GB0028483D0 (en) 2000-11-22 2000-11-22 Hydroxyethylamine HIV protease inhibitors

Publications (1)

Publication Number Publication Date
ECSP034618A true ECSP034618A (es) 2003-06-25

Family

ID=9903670

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004618A ECSP034618A (es) 2000-11-22 2003-05-21 Nuevos compuestos para usarse como inhibidores de proteasa vih

Country Status (27)

Country Link
US (1) US6472404B1 (es)
EP (1) EP1339692A1 (es)
JP (1) JP2004520283A (es)
KR (1) KR20030060953A (es)
CN (1) CN1476436A (es)
AR (1) AR031763A1 (es)
AU (2) AU2954602A (es)
BG (1) BG107839A (es)
BR (1) BR0115566A (es)
CA (1) CA2428459A1 (es)
CZ (1) CZ20031667A3 (es)
EC (1) ECSP034618A (es)
GB (1) GB0028483D0 (es)
GT (1) GT200100233A (es)
HU (1) HUP0303007A2 (es)
IL (1) IL155573A0 (es)
MA (1) MA26966A1 (es)
MX (1) MXPA03004534A (es)
NO (1) NO20032290D0 (es)
NZ (1) NZ525550A (es)
PA (1) PA8533401A1 (es)
PE (1) PE20020610A1 (es)
PL (1) PL366704A1 (es)
RU (1) RU2265016C2 (es)
SK (1) SK7602003A3 (es)
UY (1) UY27033A1 (es)
WO (1) WO2002042277A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014572B (zh) * 2004-09-15 2011-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
MY161992A (en) * 2008-03-26 2017-05-31 Daiichi Sankyo Co Ltd Novel tetrahydroisoquinoline derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.

Also Published As

Publication number Publication date
NO20032290L (no) 2003-05-21
BG107839A (bg) 2004-06-30
NO20032290D0 (no) 2003-05-21
RU2003117468A (ru) 2005-01-27
BR0115566A (pt) 2003-09-30
MXPA03004534A (es) 2003-09-10
RU2265016C2 (ru) 2005-11-27
GT200100233A (es) 2002-07-04
EP1339692A1 (en) 2003-09-03
AR031763A1 (es) 2003-10-01
CZ20031667A3 (cs) 2004-01-14
PA8533401A1 (es) 2002-10-31
WO2002042277A1 (en) 2002-05-30
CA2428459A1 (en) 2002-05-30
SK7602003A3 (en) 2004-01-08
GB0028483D0 (en) 2001-01-10
HUP0303007A2 (hu) 2003-12-29
MA26966A1 (fr) 2004-12-20
KR20030060953A (ko) 2003-07-16
AU2954602A (en) 2002-06-03
PE20020610A1 (es) 2002-07-13
JP2004520283A (ja) 2004-07-08
CN1476436A (zh) 2004-02-18
PL366704A1 (en) 2005-02-07
US6472404B1 (en) 2002-10-29
NZ525550A (en) 2004-11-26
IL155573A0 (en) 2003-11-23
AU2002229546B2 (en) 2006-05-04
UY27033A1 (es) 2002-06-20

Similar Documents

Publication Publication Date Title
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
AR049433A1 (es) Derivados de naftalina
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
ECSP078004A (es) PREPARACIÓN y USO DE COMPUESTOS COMO INHIBIDORES DE PROTEASAS
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
PE20200665A1 (es) Compuestos espirociclicos y sus metodos de preparacion y uso
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
AR062680A1 (es) Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas
PE20040479A1 (es) Inhibidores de proteasa del vih y composiciones que los contienen
UY27357A1 (es) Nuevos agentes antidiabéticos .
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR056838A1 (es) Derivados de 1,2,5-tiadiazol
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
CO5611195A2 (es) Novedosos inhibidores de la gamma secretasa
AR051391A1 (es) Compuesto de pirrolidina antagonista del receptor h3; composicion farmaceutica que lo comprende, su uso para preparar un medicamento para el tratamiento de enfermedades neurologicas y un procedimiento para su elaboracion.
AR042827A1 (es) Compuestos de furano condensados
AR054992A1 (es) Pteridinas sustituidas y uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias
AR052066A1 (es) Derivados de ciclohexano
AR041246A1 (es) Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene
PE20040757A1 (es) Derivados de benzoxazina
AR044177A1 (es) Proceso para la preparacion de trans-isomeros de derivados de la difenilazetidinona
AR040928A1 (es) Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas
AR059030A1 (es) Combinacion de derivados de triazina y estimuladores de la secrecion de insulina
AR039111A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas